BRPI0607605A2 - moléculas imunogênicas - Google Patents

moléculas imunogênicas

Info

Publication number
BRPI0607605A2
BRPI0607605A2 BRPI0607605-0A BRPI0607605A BRPI0607605A2 BR PI0607605 A2 BRPI0607605 A2 BR PI0607605A2 BR PI0607605 A BRPI0607605 A BR PI0607605A BR PI0607605 A2 BRPI0607605 A2 BR PI0607605A2
Authority
BR
Brazil
Prior art keywords
immunogenic molecules
present
stimulating
immune response
molecules
Prior art date
Application number
BRPI0607605-0A
Other languages
English (en)
Inventor
David Jackson
Weiguang Zeng
Original Assignee
Queensland Inst Med Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2005900571A external-priority patent/AU2005900571A0/en
Application filed by Queensland Inst Med Res filed Critical Queensland Inst Med Res
Publication of BRPI0607605A2 publication Critical patent/BRPI0607605A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A61K39/292—Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

MOLéCULAS IMUNOGêNICAS. A presente invenção se relaciona de forma geral ao campo de imunologia e mais particularmente a moléculas capazes de estimular uma resposta imune celular. Mais particularmente, a presente invenção fornece moléculas imunogênicas auto-adjuvantes capazes de estimular uma resposta imune à epítopos de um polipeptídeo independente do tipo de HIIA dos individuos. A presente invenção em adição contempla métodos de produção e uso de moléculas imunogênicas auto-adjuvantes e composições compreendendo a mesma utilidade em vacinação de indivíduos contra polipeptídeos específicos.
BRPI0607605-0A 2005-02-08 2006-02-08 moléculas imunogênicas BRPI0607605A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2005900571A AU2005900571A0 (en) 2005-02-08 Immunogenic molecules
PCT/AU2006/000162 WO2006084319A1 (en) 2005-02-08 2006-02-08 Immunogenic molecules

Publications (1)

Publication Number Publication Date
BRPI0607605A2 true BRPI0607605A2 (pt) 2009-09-15

Family

ID=36792838

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0607605-0A BRPI0607605A2 (pt) 2005-02-08 2006-02-08 moléculas imunogênicas

Country Status (10)

Country Link
US (1) US20100129385A1 (pt)
EP (1) EP1861426A4 (pt)
JP (1) JP2008529978A (pt)
KR (1) KR20080013850A (pt)
CN (1) CN101151280A (pt)
BR (1) BRPI0607605A2 (pt)
CA (1) CA2597008A1 (pt)
IL (1) IL185917A0 (pt)
MX (1) MX2007009598A (pt)
WO (1) WO2006084319A1 (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102256997A (zh) 2008-10-16 2011-11-23 美国辉瑞有限公司 细环病毒分离株和组合物
BRPI0923402A2 (pt) * 2008-12-24 2015-08-04 Oncotherapy Science Inc Peptídeos c10rf59 e vacinas incluindo os mesmos.
JP2012523379A (ja) 2009-04-09 2012-10-04 ザ ユニバーシティー オブ メルボルン 免疫原性組成物およびその使用
GB0907989D0 (en) * 2009-05-08 2009-06-24 Hybrid Systems Ltd Multivalent adjuvant display
US8846388B2 (en) 2009-10-16 2014-09-30 Zoetis Llc Infectious clones of torque teno virus
EP2338521A1 (en) 2009-12-28 2011-06-29 Helmholtz-Zentrum für Infektionsforschung GmbH Lipopeptide- and lipoprotein-conjugates and its use
WO2012035558A2 (en) * 2010-09-14 2012-03-22 Council Of Scientific & Industrial Research A synthetic immunogen useful for generating long lasting immunity and protection against pathogens
EP2618842B1 (en) 2010-09-22 2019-04-24 Ena Therapeutics Pty Ltd Novel immunostimulatory method
BR112013015898A2 (pt) * 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
EP2718429A1 (en) 2011-06-08 2014-04-16 Zoetis LLC Infectious clones of torque teno virus
CN113876945A (zh) 2011-10-06 2022-01-04 免疫疫苗技术有限公司 包括激活或增加tlr2活性的佐剂的脂质体组合物及其应用
CA2908042C (en) 2013-03-27 2023-01-31 Immunovaccine Technologies Inc. Method for improving the efficacy of a survivin vaccine in the treatment of cancer
EP3604271A1 (en) 2013-06-28 2020-02-05 Auckland Uniservices Limited Peptides for amino acid and peptide conjugates and conjugation process
CN107250103A (zh) 2014-12-23 2017-10-13 玛格丽特·安妮·布林布尔 氨基酸缀合物和肽缀合物以及其用途
WO2017083963A1 (en) 2015-11-18 2017-05-26 Immunovaccine Technologies Inc. Adjuvanting systems and water-free vaccine compositions comprising a polyi:c polynucleotide adjuvant and a lipid-based adjuvant
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
US11013798B2 (en) 2016-03-21 2021-05-25 South Dakota Board Of Regents Orf virus-based platform for vaccine delivery
WO2018187515A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
AU2018391325B2 (en) 2017-12-21 2024-07-11 Axelia Oncology Pty Ltd Optimised compounds
WO2020082162A1 (en) * 2018-10-26 2020-04-30 Alberta Research Chemicals Inc. Synthetic innate immune receptor ligands and uses thereof
MX2021015961A (es) 2019-06-26 2022-03-22 Ena Respiratory Pty Ltd Moleculas novedosas.
US20220347146A1 (en) * 2019-09-04 2022-11-03 Axelia Oncology Pty Ltd Cancer treatment
WO2021231767A1 (en) 2020-05-13 2021-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rsv vaccine bearing one or more p gene mutations
CN114315985A (zh) 2020-09-29 2022-04-12 硕腾服务有限责任公司 减毒猪流行性腹泻病毒
CN115216451A (zh) 2021-04-16 2022-10-21 硕腾服务有限责任公司 伪狂犬病病毒疫苗
CN118267462A (zh) 2022-12-29 2024-07-02 硕腾服务有限责任公司 接种猪以抗伪狂犬病病毒的方法
WO2024186623A1 (en) 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making dried pharmaceutical compositions
WO2024186646A1 (en) 2023-03-03 2024-09-12 BioVaxys Inc. Methods of making lipid adjuvanted compositions
WO2025128971A1 (en) 2023-12-14 2025-06-19 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rsv vaccine bearing a polynucleotide which is de-optimised and de-attenuated

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5744144A (en) * 1993-07-30 1998-04-28 University Of Pittsburgh University Patent Committee Policy And Procedures Synthetic multiple tandem repeat mucin and mucin-like peptides, and uses thereof
ES2572834T3 (es) * 1999-02-17 2016-06-02 Csl Limited Complejos inmunogénicos y métodos relacionados con los mismos
AU2001248314B2 (en) * 2000-02-18 2004-08-19 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Use of Oprl lipoprotein from pseudomonas as a Th1 inducing natural adjuvant for heterologous antigens
BR0313101A (pt) * 2002-08-12 2005-06-28 Queensland Inst Med Res Novos lipopeptìdeos imunogênicos que compreendem epitopos de linfócitos t-helper e linfócitos t citotóxicos (ctl), e métodos para sua produção e uso
AU2003250586B2 (en) * 2002-08-12 2010-09-23 The Council Of The Queensland Institute Of Medical Research Novel immunogenic lipopeptides comprising T-helper and B-cell epitopes
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof

Also Published As

Publication number Publication date
JP2008529978A (ja) 2008-08-07
IL185917A0 (en) 2008-02-09
EP1861426A4 (en) 2008-11-12
MX2007009598A (es) 2008-03-10
WO2006084319A1 (en) 2006-08-17
US20100129385A1 (en) 2010-05-27
CA2597008A1 (en) 2006-08-17
EP1861426A1 (en) 2007-12-05
KR20080013850A (ko) 2008-02-13
CN101151280A (zh) 2008-03-26

Similar Documents

Publication Publication Date Title
BRPI0607605A2 (pt) moléculas imunogênicas
HUS1800021I1 (hu) Humán anti-Il-23 ellenanyagok, készítmények, eljárások és alkalmazások
BRPI0519046A2 (pt) composição de xampu
CR7875A (es) Variantes de inmunoglobina y usos de esto
BRPI0810096A2 (pt) Anticorpo anti-epcam e seus usos
SI1957539T1 (sl) Humana monoklonska protitelesa proti protein tirozin kinazi 7 (PTK7) in njihova uporaba
IS8401A (is) Fullmanngerð mótefni gegn 4-1BB í mönnum (CD137)
CL2009000200A1 (es) Compuestos derivados de 2,7-naftiridinas-1-ona, mediadores de syk; composicion farmaceutica; y uso en el tratamiento de una enfermedad inflamatoria, respiratoria, proliferativa celular o autoinmune.
HK1199711A1 (en) Bioconjugate vaccines made in prokaryotic cells
BR112014026531A2 (pt) proteínas de ligação de antígeno ligando cd30 humano
TNSN05254A1 (en) Derivatives of 2-acylamino-4-phenylthiazole, preparation method thereof and application of same in therapeutics
CR11399A (es) ANTICUERPOS ANTI-IL-12/23p40, EPITOPES, FORMULACIONES, COMPOSICIONES, METODOS Y USOS
CR9300A (es) Uso de compuestos de hierro (iii)
EA201190285A1 (ru) Иммуногенные композиции, имеющие низкую концентрацию хлорида натрия
PA8806501A1 (es) Triazolotriazinas y triazolopirazinas y su uso
CO6290689A2 (es) Derivados de 1,2,3,4-tetrahidropirrolo[1,2]pirazina-6-carboxamidas y de 2,3,4,5-tetrahidropirrol[1,2][1,4]-diazepina -7-carboxamidas su preparacion y su aplicacion en terapeutica
PE20141826A1 (es) Uso de composiciones nutricionales que incluyen lactoferrina en apoyo a la resistencia a enfermedades y condiciones
DK1572178T3 (da) Behandling af mastalgi med 4-hydroxytamoxifen
ITRM20040586A1 (it) Epitopi antigenici dell'interleuchina-21, anticorpi relativi e loro uso in campo medico.
BRPI0510938A (pt) vitamina k1 como energizador em formulações cosméticas
DE602004015141D1 (de) Modifizierte ganzzell-, zellextrakt- und omv-basierte impfstoffe
BRPI0517782A (pt) formulações de benzotiazol e uso das mesmas
BRPI0920607A2 (pt) composição imunogênica, composição famacêutica, uso de uma ou mais proteínas de s. uberis ancoradas à sortase na preparação de um medicamento, e, métodos para proteger um animal humano ou não dos efeitos de infecção pela s. uberis, e para aumentar uma resposta imune em um animal humano ou não humano.
EA200870108A1 (ru) Мутанты фсг
CL2008001936A1 (es) Composicion vacunal que comprende un conjugado quimico entre el factor de crecimiento epidermico humano recombinante (hregf) y la proteina recombinante rp64k; donde cada molecula de rp64k se enlaza 2 moleculas de hregf, con al menos un 90% de principio activo;procedimiento de obtencion; y su uso para tratar tumores de origen epitelial.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 8A. ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2273 DE 29/07/2014.

B11T Dismissal of application maintained [chapter 11.20 patent gazette]